Pagibaximab

Pagibaximab
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target staphylococcal lipoteichoic acid
Clinical data
ATC code none
Identifiers
CAS Number 595566-61-3 N
ChemSpider none
Chemical and physical data
Formula C6462H9996N1728O2028S54
Molar mass 146,072.36 g·mol−1
 NYesY (what is this?)  (verify)

Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010, it is undergoing Phase II/III clinical trials.[1][2]

References

  1. Weisman, LE; Thackray, HM; Garcia-Prats, JA; Nesin, M; Schneider, JH; Fretz, J; Kokai-Kun, JF; Mond, JJ; Kramer, WG (2009). "Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates". Antimicrobial Agents and Chemotherapy. 53 (7): 2879–86. doi:10.1128/AAC.01565-08. PMC 2704668Freely accessible. PMID 19380597.
  2. Clinical trial number NCT00646399 for "Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis" at ClinicalTrials.gov


This article is issued from Wikipedia - version of the 10/25/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.